Acelyrin, Inc. (SLRN)

May 21, 2025 - SLRN was delisted (reason: merged into ALMS)
2.250
-0.020 (-0.88%)
Inactive · Last trade price on May 21, 2025
-47.67%
Market Cap 227.15M
Revenue (ttm) n/a
Net Income (ttm) -268.52M
Shares Out 100.95M
EPS (ttm) -2.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close 2.270
Day's Range n/a
52-Week Range 1.845 - 7.250
Beta 1.09
Analysts Hold
Price Target 9.60 (+326.67%)
Earnings Date May 14, 2025

About SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2023
Employees 83
Stock Exchange NASDAQ
Ticker Symbol SLRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SLRN stock is "Hold." The 12-month stock price forecast is $9.6, which is an increase of 326.67% from the latest price.

Price Target
$9.6
(326.67% upside)
Analyst Consensus: Hold
Stock Forecasts

News

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...

4 weeks ago - GlobeNewsWire

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today

5 weeks ago - GlobeNewsWire

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN,...

6 weeks ago - GlobeNewsWire

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (...

Other symbols: ALMS
2 months ago - Business Wire

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...

3 months ago - GlobeNewsWire

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC...

3 months ago - GlobeNewsWire

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma com...

Other symbols: ALMS
3 months ago - GlobeNewsWire

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...

4 months ago - GlobeNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisi...

Other symbols: ALMS
4 months ago - PRNewsWire

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.

Other symbols: TSLA
5 months ago - Benzinga

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile

5 months ago - GlobeNewsWire

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...

5 months ago - GlobeNewsWire

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance

6 months ago - GlobeNewsWire

Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript

Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Execut...

7 months ago - Seeking Alpha

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024

7 months ago - GlobeNewsWire

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...

7 months ago - GlobeNewsWire

Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch

Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and a...

9 months ago - Seeking Alpha

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...

9 months ago - GlobeNewsWire

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...

10 months ago - GlobeNewsWire

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep

On Wednesday, Acelyrin Inc. SLRN confirmed that it was completing a 33% reduction in its workforce.

10 months ago - Benzinga

Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript

Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs Mina Kim - C...

10 months ago - Seeking Alpha

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...

11 months ago - GlobeNewsWire

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients

1 year ago - GlobeNewsWire

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by e...

1 year ago - GlobeNewsWire

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...

1 year ago - GlobeNewsWire